Westlake BioPartners Fund I, L.P.
Known title: 10% OwnerCIK: 0001749591
Associated companies
Transaction History
| KYTX | ▼ Sell | Other | 3,787,940 | — | 2/12/2024 | View on chart |
| KYTX | ▼ Sell | Other | 735,984 | — | 2/12/2024 | View on chart |
| KYTX | ▼ Sell | Other | 3,787,940 | — | 2/12/2024 | View on chart |
| KYTX | ▼ Sell | Other | 735,984 | — | 2/12/2024 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Kyverna Reports Positive One-Year Data for Miv-cel Trials
Kyverna Therapeutics disclosed one‑year data from its Miv‑cel trials in stiff person syndrome and generalized myasthenia gravis, showing durable responses and a favorable safety profile. The CEO noted that the high disease burden supports a premium pricing strategy. These results reinforce the potential of a single‑dose therapy to reduce long‑term treatment burden.
Kyverna Reports Positive One-Year Data for Miv-cel Trials. Kyverna Therapeutics disclosed one‑year data from its Miv‑cel trials in stiff person syndrome and generalized myasthenia gravis, showing durable responses and a favorable safety profile. The CEO noted that the high disease burden supports a premium pricing strategy. These results reinforce the potential of a single‑dose therapy to reduce long‑term treatment burden.